1. **EpiPen prices far outpace cost sharing**
   - Mylan has increased their list price from $100 in 2009 to over $600 in 2016
   - Over the same period, most people would have only had their fixed copay increase from $27 to $31 while coinsurance has held steady at approximately 25-27%
   - The overall average patient cost share paid for EpiPens—including both copays and coinsurance—has decreased from 26% of list price in 2009 to 11% in 2016

2. **Price concessions negotiated by PBMs significantly reduce costs to the system**
   *(EpiPen manufacturer’s price concession (rebate) negotiated by PBMs estimated to be approximately 33%)*

3. **Of the $400 net EpiPen cost, who pays and where does the money go?**